join us
CN
Home page
About Us
Profile
Affiliates/Subsidiaries
Development History
Quality Management
Contact Us
Legal Statement
Science and Technology
R&D platform
R&D pipeline
Therapeutic Field
TheListOfProducts
International Business
APIs
Finished Products
Medical device
Download product list
Contact
News Center
News & Trends
Public information
News & Trends
27
2022-05
Updated progress of Allisartan Isoproxil and Indapamide sustained-release tablets in Phase 3 trial for the treatment of essential hypertension
24
2022-05
Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer
26
2022-04
Teriparatide Injection (Xinfutai Pro®) for Osteoporosis Approved for Commercialization
09
2022-03
Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases
04
2022-03
NMPA Approves Clinical Trials with SAL0114 Tablets for AD Agitation
17
2022-02
Salubris Announces Clinical Trial Approval of SAL0114 Tablet – Potential Clinical Depression Treatment Candidate
目前在第
1
页,
共有
4
页,
共有
21
条记录
第一页
上一页
1
2
3
4
下一页
最后一页
跳转到
页
山东体彩网